Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients withPIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer

已完结 20 由 yv 发布于 2026/1/14 10:11:25

DOI:10.1158/1538-7445.am2020-ct109
作者：K. Kalinsky,?D. Juric,?Philippe Bédard,?Mafalda Oliveira,?A. Cervantes,?E. Hamilton,?I. Krop,?N. Turner,?P. Schmid,?A. Varga,?A. Italiano,?Zachary W. Veitch,?C. Saura,?V. Gambardella,?S. Cheeti,?N. K
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Background:PIK3CA encodes the PI3K p110α subunit, and dysregulating mutations are widely seen in breast cancer (BC) and other solid tumors. GDC-0077 (G) is a potent p110α-selective inhibitor

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierIntegrating lipidomics and metabolomics to reveal biomarkers of fat deposition in chicken meat